EBITDA: Income before interest, taxes, depreciation and amortization.
Monopar Therapeutics Inc. (MNPR) had EBITDA of $-6.16M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-5.20M |
|
-- |
|
-- |
|
$6.16M |
|
$-6.16M |
|
$0.95M |
|
$-5.20M |
|
$-5.20M |
|
$-5.20M |
|
$-5.20M |
|
$-5.20M |
|
$-5.20M |
|
$-6.16M |
|
|
EBITDA |
$-6.16M |
7.41M |
|
7.41M |
|
$-0.64 |
|
$-0.64 |
|
| Balance Sheet Financials | |
$140.46M |
|
-- |
|
$0.25M |
|
$140.72M |
|
$2.74M |
|
-- |
|
$0.15M |
|
$2.89M |
|
$137.83M |
|
$137.83M |
|
$137.83M |
|
6.69M |
|
| Cash Flow Statement Financials | |
$-12.20M |
|
$-63.45M |
|
$91.57M |
|
$45.82M |
|
$61.83M |
|
$16.02M |
|
$4.84M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
51.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.20M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.77% |
|
-3.77% |
|
-3.70% |
|
-3.77% |
|
$20.60 |
|
$-1.65 |
|
$-1.65 |
|